Lexaria Bioscience (LEXX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lexaria Bioscience has formed a new Scientific Advisory Board to enhance its drug delivery platform technology, with John Docherty, a seasoned expert in the pharmaceutical sector, as the Chairman. The board, comprising experts in pharmaceutical development, aims to guide the company’s strategic plans towards successful commercialization.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
